Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04336215 · ClinicalTrials.gov registry record
Rutgers COVID-19 Cohort Study
A clinical trial, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- 829
- Enrollment target
NCT04336215: Completed study, sponsored by Rutgers, The State University of New Jersey.
NCT04336215 is a clinical trial that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 829 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04336215 has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- 829 participants
- Enrollment target
Study Summary
Our long-term goal is to protect the health care workforce (HCW) caring for SARS-CoV-2-infected patients, their families, communities, and the general population. Our specific objective is to rapidly establish a prospective cohort to characterize the factors related to viral transmission and disease severity in a large healthcare system. We addressed this hypothesis by recruiting and longitudinally following 546 HCW and a comparison group of 283 non-HCW within a large academic health system, Rutgers Biomedical and Health Sciences (RBHS). By intensively following participants over a several year period (2020-2024) and collecting serial biospecimens (nasopharyngeal/throat swabs, blood, and saliva) and questionnaire data at multiple time points, we will uniquely characterize SARS-CoV-2 transmission and risk factors for COVID-19 among HCW and our larger academic community.
Primary Outcome
Prevalence and 95% confidence intervals, using standard epidemiological methods (Aims 1, 2, and 3).
Interventions
- OTHER Non-Interventional
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 829 participants |
| Start Date | 2020-04-07 |
| Est. Completion | 2024-08-31 |
What the finished NCT04336215 record still lists
NCT04336215 is an observational study that tracks outcomes without assigning an intervention. The registered 829 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional is the first listed.
NCT04336215 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04336215 about?
NCT04336215 is a clinical study titled "Rutgers COVID-19 Cohort Study". Our long-term goal is to protect the health care workforce (HCW) caring for SARS-CoV-2-infected patients, their families, communities, and the general population. Our specific objective is to rapidly establish a prospective cohort to characterize the factors related to viral transmission and disease...
What is the current status of trial NCT04336215?
This trial is currently completed. The enrollment target is 829 participants. The study started on 2020-04-07. Estimated completion is 2024-08-31.
What interventions are being tested in trial NCT04336215?
The interventions under investigation include: Non-Interventional (OTHER).
Who is sponsoring clinical trial NCT04336215?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05067283 · 830 participants · Phase 1
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
- NCT06592924 · 830 participants · Phase 3
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- NCT06868277 · 830 participants · Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- NCT05124808 · 828 participants · NA
Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI